Programmed death ligand-1 expression in non-small cell lung cancer
Vamsidhar Velcheti(Yale University), David L. Rimm(Yale University), Lieping Chen(Fujian Medical University), Kurt A. Schalper(Yale Cancer Center), Daniel Carvajal(Yale University), Valsamo Anagnostou(Bloomberg (United States)), Scott Gettinger(Yale Cancer Center), Mario Sznol(Yale Cancer Center), Konstantinos N. Syrigos(National and Kapodistrian University of Athens), Roy S. Herbst(The University of Texas MD Anderson Cancer Center)
Cited by 753
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Lung Cancer
|New England Journal of Medicine|2008|2.4k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k